Survey highlights Hungarian failings for cancer patients

3 June 2019

A trade group representing pharma in Hungary is trying to take a more proactive approach to improving cancer outcomes in light of a survey showing scope for improvement in the central European country.

The study was commissioned by the Association of Innovative Pharmaceutical Manufacturers (AIPM) and found that, although the overall impression of Hungarian patients regarding cancer care was found to be positive, many believe that the practical elements related to the patient pathway management is the main problem that they face, rather than the quality of treatments.

The AIPM’s survey is being published to support the establishment of an efficient cancer control strategy in Hungary and wants to assist in the prevention and in the identification of the symptoms via its newly-launched website.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK